Last edition
News about
EMA Recommends Approval of Jascayd for IPF and Progressive Pulmonary Fibrosis
Jascayd receives positive CHMP recommendation for approval in Europe to treat Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF), addressing major unmet needs in severe and life-threatening lung diseases.
Camizestrant Plus CDK4/6 Inhibitor Recommended for EU Approval in Advanced ER-Positive Breast Cancer
Camizestrant plus a CDK4/6 inhibitor receives CHMP recommendation for EU approval in first-line advanced ER-positive breast cancer, supported by phase 3 SERENA-6 trial results showing a 56 percent reduction in disease progression or death.
Ichnos Glenmark Innovation Unveils Novel Multispecific Antibody Candidate for Solid Tumour Treatment
Ichnos Glenmark Innovation has introduced ISB 2301, a next-generation multispecific antibody designed to activate immune cells and target solid tumours through a multi-mechanism approach aimed at improving cancer treatment outcomes.
Qihan Biotech Secures US FDA IND Clearance for Next-Generation Universal CAR-T Therapy QT-019C
Qihan Biotech has received US FDA Investigational New Drug clearance for QT-019C, an off-the-shelf universal CAR-T therapy designed to improve safety, accessibility and treatment outcomes for patients with autoimmune diseases.
Incyte and Genesis Molecular AI have expanded their strategic collaboration to deploy advanced molecular AI technologies and proprietary research data, aiming to accelerate drug discovery and develop next-generation therapies through AI-powered molecular design.
Dr. Jitendra Singh Launches UMMID Program, Highlights Future of Genomic and Precision Medicine
Dr. Jitendra Singh dedicates the UMMID Program to the nation, highlighting the growing role of genomic and precision medicine in advancing early intervention, personalised treatment, and affordable healthcare for rare genetic disorders in India.
Merck Doses First Patient in Phase 3 Trial of Investigational ADC for Colorectal Cancer
Merck announces first patient dosing in a phase 3 trial evaluating investigational Antibody Drug Conjugate (ADC) precemtabart tocentecan for metastatic colorectal cancer, targeting CEACAM5 expressed in most colorectal tumors.
Alembic Pharmaceuticals Receives US FDA Final Approval for Levothyroxine Sodium Tablets
Alembic Pharmaceuticals receives final US Food and Drug Administration (FDA) approval for multiple strengths of Levothyroxine Sodium Tablets USP, expanding its portfolio of generic therapies for thyroid disorder management.
Bayer Receives FDA Priority Review for Kerendia in Type 1 Diabetes-Related Kidney Disease
Bayer receives US Food and Drug Administration (FDA) Priority Review (PR) for supplemental approval of Kerendia to treat adults with Type 1 Diabetes (T1D) and Chronic Kidney Disease (CKD), potentially becoming the first Mineralocorticoid Receptor Antagonist (MRA) approved for this patient population.
Gilead Sciences and Kite Pharma to present new ASCO and EHA 2026 data highlighting progress in Antibody Drug Conjugates (ADCs) and CAR T-cell therapies, including updates on Trodelvy and anito-cel for difficult-to-treat cancers.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy